Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer

NCT01915485 is registered in ClinicalTrials.gov with Instituto Nacional de Cancer, Brazil as lead sponsor.

NCT NCT01915485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01915485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer
Lead sponsor
Instituto Nacional de Cancer, Brazil
Phase
Phase 4
Overall status
Unknown status
Start date
August 31, 2013
Completion date
February 28, 2017
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

medullary thyroid cancer